Vaccitech (NASDAQ:VACC) Stock Price Down 4.2%

Vaccitech plc (NASDAQ:VACC) fell 4.2% during mid-day trading on Tuesday . The company traded as low as $2.51 and last traded at $2.53. 18,050 shares were traded during mid-day trading, a decline of 93% from the average session volume of 244,643 shares. The stock had previously closed at $2.64.

Vaccitech Stock Performance

The business’s fifty day moving average is $2.75 and its 200-day moving average is $3.14. The firm has a market cap of $104.46 million, a P/E ratio of -1.82 and a beta of -0.40.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Baird Financial Group Inc. acquired a new stake in Vaccitech during the 4th quarter valued at approximately $217,000. Renaissance Technologies LLC increased its position in Vaccitech by 198.2% during the 2nd quarter. Renaissance Technologies LLC now owns 34,000 shares of the company’s stock valued at $70,000 after purchasing an additional 22,600 shares during the period. Janney Montgomery Scott LLC acquired a new stake in Vaccitech during the 3rd quarter valued at approximately $46,000. Citadel Advisors LLC acquired a new stake in Vaccitech during the 2nd quarter valued at approximately $31,000. Finally, Millennium Management LLC increased its position in Vaccitech by 32.8% during the 4th quarter. Millennium Management LLC now owns 40,388 shares of the company’s stock valued at $97,000 after purchasing an additional 9,967 shares during the period. Institutional investors own 26.13% of the company’s stock.

Vaccitech Company Profile

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer.